Alnylam Pharmaceuticals reported $32.66M in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 6.68M 1.48M
Alexion Pharmaceuticals ALXN:US $ 125.4M 26.8M
Alnylam Pharmaceuticals ALNY:US $ 32.66M 2.41M
Amgen AMGN:US $ 1609M 28M
Biocryst Pharmaceuticals BCRX:US $ 0.62M 0.27M
Biomarin Pharmaceutical BMRN:US $ 103.54M 23.52M
Bluebird Bio BLUE:US $ 19.7M 4.4M
Gw Pharmaceuticals GWPH:US $ 11.81M 1.39M
Intercept Pharmaceuticals ICPT:US $ 0.66M 0.04M
IONIS PHARMACEUT IONS:US $ 3M 0.04M
Moderna Inc MRNA:US 722M 28M
Neurocrine Biosciences NBIX:US $ 4.2M 1.1M
Novartis NVS:US $ 3848M 94M
Ptc Therapeutics PTCT:US $ 6.54M 0.82M
Regeneron Pharmaceuticals REGN:US $ 453.2M 240.5M
Sarepta Therapeutics SRPT:US $ 23.44M 3.93M
Takeda 4502:JP Y 275797M 34533M
Ultragenyx Pharmaceutical RARE:US $ 4.18M 1.04M
Vertex Pharmaceuticals VRTX:US $ 236.51M 8.54M
YTE INCY:US $ 34.47M 1.84M